Brief: Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
06/12/2023 13:06
Dec 6 (Reuters) - Cocrystal Pharma Inc COCP.O :
* COCRYSTAL PHARMA ANNOUNCES FIRST-PATIENT-IN FOR PHASE 2A
HUMAN
CHALLENGE STUDY EVALUATING ORAL CC-42344 IN PANDEMIC AND
SEASONAL INFLUENZA A
Source text for Eikon: ID:nGNX9L3BCx
Further company coverage: COCP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway